Endo raises full-year guidance despite Q3 income drop
This article was originally published in Scrip
Endo Pharmaceuticals reported a drop of 25% in income for the third quarter to $49 million, primarily owing to Indevus acquisition expenses. However, revenues increased by 14% to $361 million and the company is raising its guidance for full-year figures.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.